Efficacy and Safety of Finerenone in Type 2 Diabetes Individuals with Diabetic Kidney Disease

Efficacy and Safety of Finerenone in Type 2 Diabetes Individuals with Diabetic Kidney Disease - Efficacy and Safety of Finerenone in Type 2 Diabetes Individuals with Diabetic Kidney Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054821

Enrollment

Registered

2024-08-10

Start date

2024-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Individuals with Diabetic Kidney Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes outpatients with diabetic kidney disease who required treatment with Finerenone as indicated from April 1, 2023, to August 31, 2024.

Exclusion criteria

Exclusion criteria: No particular details

Design outcomes

Primary

Measure	Time frame
Efficacy: Change in Urine Albumin-to-Creatinine Ratio (UACR) from baseline Safety: Change in Serum Potassium Levels from baseline	—

Countries

Japan

Contacts

Public ContactYuji Kawaguchi

Minami Osaka Hospital Department of Internal Medicine

y.kawaguchi@minamiosaka.com0666850221

Outcome results